ORGO

Organogenesis Holdings Inc. Class A Common Stock (ORGO) | Rumor.io

Organogenesis Holdings

ORGO

Attention (50-day avg)0%

Attention rank (50-day avg)#4,105

Bullish sentiment (50-day avg)100%

Price to earnings ratio17.1

Market capitalization177.6M

Earnings per share-0.76

Dividend yield (TTM)—

Revenue (annual)563M

Net income (annual)37M

Social

What share of all stock conversation is about ORGO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

May 13

Organogenesis Holdings Inc. ($ORGO) stock has been mentioned in relation to its potential price movement, with some users speculating about its performance compared to other stocks.
The company's recent news, particularly regarding its Renu product, has been cited as a possible reason for the stock's upward trend.
There is a question about how the FDA shake-up may impact Organogenesis Holdings Inc.'s approval chances for its products.

Generated by AI

Sentiment

Of the messages about ORGO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	93.28% +9.93
Bearish	—	—	—	6.72% -9.93

Bullish· Apr 7

ORGO's PuraPly product, along with Apligraft and Dermagraft, may give the company a dominant market position in skin substitutes by 2027.
The potential approval of Renu by December 2026, with a release date in 2027, could significantly increase ORGO's revenue and make it an attractive target for buyouts by megacap companies.
ORGO's recent trial success with PuraPlyAM has led to a 17.4% jump in the company's shares, with some analysts predicting the stock could reach over $20.

Bearish· Feb 28

The market makers and algorithms are the primary counterparty to retail traders, and these stocks are manipulated to reach certain levels before being dumped.
The stock may drop towards $4.8 support line being crossed, and the author warns against holding onto the stock in this market.
The large float and expectation of a drug move may lead to disappointment, and the author notes that short sellers are already starting to take positions.

Generated by AI

Topics

Of the messages about ORGO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	64.09%
Analysts	—	—	—	1.2%
Controversies	—	—	—	1.2%
Earnings	—	—	—	5.33%
Macro	—	—	—	4.47%
Technical Analysis	—	—	—	23.71%

Dec 16

Organogenesis Holdings Inc. ($ORGO) plans to file a Biologics License Application (BLA) for ReNu, a treatment for knee osteoarthritis pain, before the end of December 2025.
The FDA has confirmed that the ReNu clinical development program, including two large Phase 3 randomized controlled trials, is appropriate for BLA submission.
ReNu is positioned to tap into significant Total Addressable Markets (TAMs) in the knee osteoarthritis treatment and global wound care sectors, valued at approximately $3.5 billion and $6.8 billion, respectively.

Generated by AI

Community

Of the messages about ORGO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	47.62%
Newcomers	100%	100%	100%	52.38%

Regulars· May 24

Organogenesis Holdings Inc. has seen a significant increase in its stock price, with a 19% gain since the previous day's close, and a 18% jump after a price target was announced at $10 per share by BTIG.
The stock's medium float has led to a relatively large volume trade, with shares currently trading at $4.09.
Analysts at BTIG have made a bullish call on Organogenesis Holdings Inc., upgrading its rating to Buy from Neutral and setting a price target of $10 per share.

Newcomers· Nov 19

New investors are focusing on Organogenesis Holdings Inc. ($ORGO) as a top pick for their portfolio, citing its potential for growth.
Users are expressing their enthusiasm for investing in $ORGO, with some indicating they are going "all in" on the company.
A comparison is being made between $ORGO and other companies, with some users suggesting it is a strong choice for their portfolio.

Generated by AI

News

Organogenesis Holdings (ORGO) Stock Fair Value Moves Lower After Guidance Cut And Analyst Caution

1mo agoYahoo Finance

Organogenesis Holdings (ORGO) Is Down 21.5% After Slashing 2026 Guidance And Launching Equity Offering – Has The Bull Case Changed?

1mo agoYahoo Finance

Organogenesis Holdings Inc. Q2 2026 Earnings Call Summary

1mo agoYahoo Finance

Organogenesis Q2 Earnings Call Highlights

1mo agoYahoo Finance

Organogenesis Holdings enters at-the-market sales agreement for up to $75 million

1mo agoInvesting.com

Organogenesis: Q2 Earnings Snapshot

1mo agoYahoo Finance

Also Discussed

Investors talking about ORGO also mention

#	Name	Attention
1	Saul Centers, Inc.BFS	0%new
2	Sana Biotechnology Inc.SANA	0%0
3	MiMedx Group, Inc.MDXG	0%0
4	GSD - WisdomTree Global SmallCap Dividend Fund	——
5	Syra Health Corp.SYRA	0%0
6	PMX - PIMCO Municipal Income Fund III	——
7	SPS Commerce, Inc.SPSC	0%new
8	AvalonBay Communities, Inc.AVB	0%new
9	Primis Financial Corp.FRST	0%0
10	First Trust Nasdaq-100 Select Equal Weight ETFQQEW	0.01%new

Organogenesis Holdings Inc. Class A Common Stock

Healthcare
Drug Manufacturers - Specialty & Generic

Organogenesis Holdings Inc. Class A Common Stock represents ownership in Organogenesis Holdings Inc., a regenerative medicine company focused on developing, manufacturing, and commercializing products for advanced wound care and surgical and sports medicine. The company’s portfolio includes bioactive and acellular biomaterials designed to support healing across chronic and acute wound applications, as well as surgical biologics used in orthopedic and spine-related settings. Its products are used by healthcare providers across hospitals, clinics, and other care environments that treat patients with complex wounds and tissue repair needs. Organogenesis Holdings Inc. serves a specialized role in the broader healthcare market by supplying biologic and tissue-based solutions aimed at improving clinical care pathways in wound management and regenerative therapies. The company is headquartered in Canton, Massachusetts.

Website

Location

85 Dan Road

Canton, MA, 02021

United States

Social

What share of all stock conversation is about ORGO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

May 13

Organogenesis Holdings Inc. ($ORGO) stock has been mentioned in relation to its potential price movement, with some users speculating about its performance compared to other stocks.
The company's recent news, particularly regarding its Renu product, has been cited as a possible reason for the stock's upward trend.
There is a question about how the FDA shake-up may impact Organogenesis Holdings Inc.'s approval chances for its products.

Generated by AI

Sentiment

Of the messages about ORGO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	93.28% +9.93
Bearish	—	—	—	6.72% -9.93

Bullish· Apr 7

ORGO's PuraPly product, along with Apligraft and Dermagraft, may give the company a dominant market position in skin substitutes by 2027.
The potential approval of Renu by December 2026, with a release date in 2027, could significantly increase ORGO's revenue and make it an attractive target for buyouts by megacap companies.
ORGO's recent trial success with PuraPlyAM has led to a 17.4% jump in the company's shares, with some analysts predicting the stock could reach over $20.

Bearish· Feb 28

The market makers and algorithms are the primary counterparty to retail traders, and these stocks are manipulated to reach certain levels before being dumped.
The stock may drop towards $4.8 support line being crossed, and the author warns against holding onto the stock in this market.
The large float and expectation of a drug move may lead to disappointment, and the author notes that short sellers are already starting to take positions.

Generated by AI

Topics

Of the messages about ORGO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	64.09%
Analysts	—	—	—	1.2%
Controversies	—	—	—	1.2%
Earnings	—	—	—	5.33%
Macro	—	—	—	4.47%
Technical Analysis	—	—	—	23.71%

Dec 16

Organogenesis Holdings Inc. ($ORGO) plans to file a Biologics License Application (BLA) for ReNu, a treatment for knee osteoarthritis pain, before the end of December 2025.
The FDA has confirmed that the ReNu clinical development program, including two large Phase 3 randomized controlled trials, is appropriate for BLA submission.
ReNu is positioned to tap into significant Total Addressable Markets (TAMs) in the knee osteoarthritis treatment and global wound care sectors, valued at approximately $3.5 billion and $6.8 billion, respectively.

Generated by AI

Community

Of the messages about ORGO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	47.62%
Newcomers	100%	100%	100%	52.38%

Regulars· May 24

Organogenesis Holdings Inc. has seen a significant increase in its stock price, with a 19% gain since the previous day's close, and a 18% jump after a price target was announced at $10 per share by BTIG.
The stock's medium float has led to a relatively large volume trade, with shares currently trading at $4.09.
Analysts at BTIG have made a bullish call on Organogenesis Holdings Inc., upgrading its rating to Buy from Neutral and setting a price target of $10 per share.

Newcomers· Nov 19

New investors are focusing on Organogenesis Holdings Inc. ($ORGO) as a top pick for their portfolio, citing its potential for growth.
Users are expressing their enthusiasm for investing in $ORGO, with some indicating they are going "all in" on the company.
A comparison is being made between $ORGO and other companies, with some users suggesting it is a strong choice for their portfolio.

Generated by AI

Organogenesis Holdings

Social

May 13

Bullish· Apr 7

Bearish· Feb 28

Dec 16

Regulars· May 24

Newcomers· Nov 19

Organogenesis Holdings (ORGO) Stock Fair Value Moves Lower After Guidance Cut And Analyst Caution

Organogenesis Holdings (ORGO) Is Down 21.5% After Slashing 2026 Guidance And Launching Equity Offering – Has The Bull Case Changed?

Organogenesis Holdings Inc. Q2 2026 Earnings Call Summary

Organogenesis Q2 Earnings Call Highlights

Organogenesis Holdings enters at-the-market sales agreement for up to $75 million

Organogenesis: Q2 Earnings Snapshot

Also Discussed

Organogenesis Holdings Inc. Class A Common Stock

Company Information

Location

Organogenesis Holdings (ORGO) Stock Fair Value Moves Lower After Guidance Cut And Analyst Caution

Organogenesis Holdings (ORGO) Is Down 21.5% After Slashing 2026 Guidance And Launching Equity Offering – Has The Bull Case Changed?

Organogenesis Holdings Inc. Q2 2026 Earnings Call Summary

Organogenesis Q2 Earnings Call Highlights

Organogenesis Holdings enters at-the-market sales agreement for up to $75 million

Organogenesis: Q2 Earnings Snapshot

Also Discussed

Social

May 13

Bullish· Apr 7

Bearish· Feb 28

Dec 16

Regulars· May 24

Newcomers· Nov 19